Stroke:房颤并发心力衰竭患者左心功能不全程度、症状与栓塞风险之间关系

2015-02-02 李志行 译 MedSci原创

目前在房颤患者中左心室功能障碍(LVSD)、心力衰竭(HF)症状、栓塞风险之间关系方面的数据十分有限。研究方法:HF患者参与氯吡格雷联合厄贝沙坦预防房颤患者血管事件(ACTIVE)试验,但并不随机分配口服抗凝药物,他们被归类为保存射血分数型心衰和减低射血分数型心衰。如果是减低型,LVSD被分为轻度、中度或重度。症状通过纽约心脏病协会分级进行定量。主要结果为中风、短暂性脑缺血发作和全身性栓塞的综合。

目前在房颤患者中左心室功能障碍(LVSD)、心力衰竭(HF)症状、栓塞风险之间关系方面的数据十分有限。

研究方法:


HF患者参与氯吡格雷联合厄贝沙坦预防房颤患者血管事件(ACTIVE)试验,但并不随机分配口服抗凝药物,他们被归类为保存射血分数型心衰和减低射血分数型心衰。如果是减低型,LVSD被分为轻度、中度或重度。症状通过纽约心脏病协会分级进行定量。主要结果为中风、短暂性脑缺血发作和全身性栓塞的综合。




研究结果:

以3487名接受抗血小板治疗的HF患者做为基线。在这些患者中,有969名(46.8%)保存射血分数型HF患者和1103名 (53.2%)减低射血分数型HF患者。在3.6年的平均随访期内,386名患者首次发生中风、短暂性脑缺血发作或全身性栓塞。栓塞最强的独立预测指标为年龄 ≥75 岁(HR 2.55; CI, 1.85–3.53),中风或短暂性脑缺血发作先兆(HR 2.07; 95% CI, 1.65–2.60),和女性(HR 1.37; CI, 1.11–1.69)。然而,射血分数<0.50,LVSD程度和纽约心脏病协会分级并没有预测栓塞的发生。保存射血分数型HF患者与减低射血分数型HF患者表现出的发生栓塞的风险是相似的:每100人年中4.3% 对4.4%(HR 1.01; 95% CI, 0.78–1.31)。在LVSD分类(P for trend =0.96)和纽约心脏病协会分级(P for trend =0.57)中,发生栓塞的风险是相似的。





研究结论:

在ACTIVE试验中的HF患者中,无论是患有LVSD还是症状严重程度都不能影响发生栓塞的风险。

原始出处:

Roopinder K. Sandhu, Stefan H. Hohnloser, Marc A. Pfeffer, Fei Yuan, Robert G. Hart, Salim Yusuf, Stuart J. Connolly, Finlay A. McAlister, and Jeff S. Healey
Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure
Stroke 2015; first published on January 27 2015 as doi:10.1161/STROKEAHA.114.007140

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757646, encodeId=b5641e5764629, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 13 17:39:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16207, encodeId=2ed81620eab, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:55:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15474, encodeId=621d154e49f, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:54:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378759, encodeId=414c13e875907, content=<a href='/topic/show?id=b60d5089495' target=_blank style='color:#2F92EE;'>#心功能不全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50894, encryptionId=b60d5089495, topicName=心功能不全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465640, encodeId=a69b14656408e, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2015-09-13 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757646, encodeId=b5641e5764629, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 13 17:39:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16207, encodeId=2ed81620eab, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:55:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15474, encodeId=621d154e49f, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:54:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378759, encodeId=414c13e875907, content=<a href='/topic/show?id=b60d5089495' target=_blank style='color:#2F92EE;'>#心功能不全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50894, encryptionId=b60d5089495, topicName=心功能不全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465640, encodeId=a69b14656408e, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2015-02-17 chinayinhan

    已阅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1757646, encodeId=b5641e5764629, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 13 17:39:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16207, encodeId=2ed81620eab, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:55:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15474, encodeId=621d154e49f, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:54:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378759, encodeId=414c13e875907, content=<a href='/topic/show?id=b60d5089495' target=_blank style='color:#2F92EE;'>#心功能不全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50894, encryptionId=b60d5089495, topicName=心功能不全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465640, encodeId=a69b14656408e, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
    2015-02-15 午夜星河

    明白

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1757646, encodeId=b5641e5764629, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 13 17:39:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16207, encodeId=2ed81620eab, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:55:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15474, encodeId=621d154e49f, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:54:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378759, encodeId=414c13e875907, content=<a href='/topic/show?id=b60d5089495' target=_blank style='color:#2F92EE;'>#心功能不全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50894, encryptionId=b60d5089495, topicName=心功能不全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465640, encodeId=a69b14656408e, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757646, encodeId=b5641e5764629, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun Sep 13 17:39:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16207, encodeId=2ed81620eab, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:55:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15474, encodeId=621d154e49f, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:54:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378759, encodeId=414c13e875907, content=<a href='/topic/show?id=b60d5089495' target=_blank style='color:#2F92EE;'>#心功能不全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50894, encryptionId=b60d5089495, topicName=心功能不全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465640, encodeId=a69b14656408e, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Wed Feb 04 04:39:00 CST 2015, time=2015-02-04, status=1, ipAttribution=)]

相关资讯

控制房颤心室率的药物知多少

在以往多期的文章中,我们曾详细介绍过房颤的射频消融及抗凝治疗。尽管对于房颤患者最理想的治疗莫过于恢复窦性心律,但对于左房内径过大(一般大于55mm)、合并没有纠正的二尖瓣狭窄及其它器质性心脏病的房颤来说复律成功的比率不高,或者即使复为窦性心律也很难维持,这种情况下可退而其次应用药物减慢较快的心室率以改善症状。今天,小编就带领大家简单了解一下这类药物。 β受体阻滞剂为临床中控制房颤心室率最

研究:肥胖增房颤风险

古人言:腰带长,寿命短,一胖百病缠。肥胖对健康的影响越来越受到人们的关注。那么如何判断肥胖呢?这里推荐一个简单的方法,体重指数法。体重指数(BMI)的计算公式:BMI=体重(Kg)/身高(m)2BMI<25为正常,25≤BMI<30为超重,BMI≥30为肥胖。 有研究表明肥胖与房颤之间存在相关性。该研究共入选的5282例受试者,研究者根据体重指数(BMI)将入选者分为正常体重组、超重组和

Ann Intern Med:应警惕大出血和血栓栓塞风险

英国和丹麦联合研究表明,在房颤患者中,应用非类固醇类抗炎药(NSAID)为大出血和血栓栓塞的独立危险因素。短期应用NSAID亦与出血风险升高相关。论文11月18日发表于《内科学年鉴》杂志。 研究纳入1997-2011年间房颤住院患者150900例,中位年龄75岁,47%为女性。利用考克斯(Cox)模型评估NSAID与抗血栓治疗期间大出血和血栓栓塞的绝对风险。共有53732例(35.6%)

房颤患者卒中预防风险CHA2DS2-VASc评分公式

房颤患者卒中预防风险CHA2DS2-VASc评分公式

JACC:房颤卒中风险评估1分的患者口服抗凝药是否具有受益?

目前的指南对于房颤患者的管理,建议基于风险口服抗凝药预防卒中。然而,未使用预防性治疗的房颤相关性卒中风险存在很大差异。高风险患者,在日常管理中不存在差异,因为都服用口服抗凝药治疗;低风险患者,其治疗取决于卒中风险评估。欧洲和美国指南都建议使用CHA2DS2-VASc评分经行分类。CHA2DS2-VASc为1分的低风险患者,欧洲心脏协会建议使用维生素拮抗剂,或者选用效果更好的口服抗凝药。然而,C

JACC:支持用植入设备检测无症状房颤的十点理由

随着起搏器、心脏再同步化治疗,以及植入式心律转复除颤器(ICD)等广泛进入临床,之前未确诊的心律失常特别是房颤,也被越来越多地被发现。那么如何看待这些无症状的被检测出的房颤?美国心脏学院专家会员Aman Chugh提出了以下十点认识。 1.对于伴有隐源性脑卒中的患者,植入式设备的房颤检出率要比传统的监测方式如心电图或动态心电图更高。 2、对于发生脑卒中的患者,30天内事件监测相对应